Key result
Apixaban without aspirin cuts major events ~34% vs VKA plus aspirin in AF with recent ACS/PCI.
Why the study?
The optimal antithrombotic regimen for patients with atrial fibrillation who had an ACS or undergone PCI is not known.
RCT (n=4,614)
Open-label
2 x 2 factorial
Yes
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The current analysis of the AUGUSTUS trial overcomes these disadvantages of meta-analyses and includes the added dimension of triple therapy with aspirin and a P2Y12 inhibitor plus either apixaban or a VKA. It demonstrated that dual therapy is superior to triple therapy for the combined primary endpoint, which included ischemic and bleeding events, and that apixaban is superior to VKA for dual therapy with a P2Y12 inhibitor.”
“It makes the case for the so-called default strategy where most patients can be managed with dual therapy when they head home from the hospital.”
“Now, [we show] this is the safest and the most efficacious strategy for a composite endpoint that includes cardiovascular hospitalizations, bleeding, and all cause deaths. These positive results were driven primarily because of less bleeding, but also went in the same direction for cardiovascular hospitalizations.... It was good to see the results were aligned with the primary AUGUSTUS result but expanded now for a combination of bleeding and cardiovascular hospitalizations.”
BACKGROUND The optimal antithrombotic regimen for patients with atrial fibrillation (AF) who had an acute coronary syndrome (ACS) or have undergone percutaneous coronary intervention (PCI) is not known. OBJECTIVES The authors sought to determine which antithrombotic regimen best balances safety and efficacy. METHODS AUGUSTUS, a multicenter 2 × 2 factorial design randomized trial compared apixaban with vitamin K antagonist (VKA) and aspirin with placebo in patients with AF with recent ACS and/or PCI treated with a P2Y12 inhibitor. We conducted a 4-way analysis comparing safety and efficacy outcomes in the 4 randomized groups. The primary outcome was a composite of all-cause death, major or clinically relevant nonmajor bleeding, or hospitalization for cardiovascular causes over 6-month follow-up. Secondary outcomes included individual components of the primary endpoint. RESULTS A total of 4,614 patients were enrolled. All patients were treated with a P2Y12 inhibitor. The primary endpoint occurred in 21.9% of patients randomized to apixaban plus placebo, 27.3% randomized to apixaban plus aspirin, 28.0% randomized to VKA plus placebo, and 33.3% randomized to VKA plus aspirin. Rates of major or clinically relevant nonmajor bleeding and hospitalization for cardiovascular causes were lower with apixaban and placebo compared with the other 3 antithrombotic strategies. There was no difference between the 4 randomized groups with respect to all-cause death. CONCLUSIONS In patients with AF and a recent ACS and/or PCI, an antithrombotic regimen that included a P2Y12 inhibitor and apixaban without aspirin resulted in a lower incidence of the composite of death, bleeding, or cardiovascular hospitalization than regimens including VKA, aspirin, or both. (An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients with Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Intervention; NCT02415400).
No takes yet. Share an insight, caveat, or question.
Berwanger et al. (2024) conducted an RCT in Atrial fibrillation with recent ACS and/or PCI (n=4,614). Apixaban plus placebo vs. Vitamin K antagonist (VKA) plus aspirin was evaluated on Composite of all-cause death, major or clinically relevant nonmajor bleeding, or hospitalization for cardiovascular causes. Apixaban without aspirin resulted in a lower incidence of death, bleeding, or cardiovascular hospitalization compared to VKA plus aspirin in patients with AF and recent ACS/PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: